je.st
news
Tag: rsv
Eastside Distilling's Burnside Buckman RSV Bourbon - Product Launch
2018-10-16 12:17:00| Daily beverage news and comment - from just-drinks.com
Publicly-listed craft spirits producer Eastside Distilling is celebrating its tenth anniversary with the release of a ten-year-old Bourbon.
Tags: product
launch
bourbon
rsv
Antibiotic Against Superbug Biofilms, RSV
2016-06-01 06:14:55| drugdiscoveryonline Home Page
A potential drug therapy developed at the University of Pittsburgh Center for Vaccine Research (CVR) has proven effective against tough bacterial biofilms and a deadly respiratory virus simultaneously
Tags: antibiotic
rsv
biofilms
superbug
Novavax: Early study indicates its vaccine effective vs. RSV
2015-08-11 03:06:09| Biotech - Topix.net
Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable Americans - babies and senior citizens. If further testing by vaccine developer Novavax Inc. goes well, in a few years the biotech company's genetically engineered shot could become the first vaccine approved against respiratory syncytial virus, or RSV.
Tags: study
early
effective
vs
Novavax: Early study indicates its vaccine effective vs. RSV
2015-08-11 03:06:08| Biotech - Topix.net
Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable people - babies and senior citizens. If further testing by vaccine developer Novavax Inc. goes well, in a few years the biotech company's genetically engineered shot could become the first vaccine approved against respiratory syncytial virus, or RSV.
Tags: study
early
effective
vs
Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at Icaac
2014-09-07 08:03:23| Biotech - Topix.net
Novavax, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody."
Tags: data
presents
induced
antibody